Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Результаты хирургического лечения больных диссеминированными гастроинтестинальными стромальными опухолями
Результаты хирургического лечения больных диссеминированными гастроинтестинальными стромальными опухолями
Абу-Хайдар О.Б., Неред С.Н., Архири П.П. и др. Результаты хирургического лечения больных диссеминированными гастроинтестинальными стромальными опухолями. Современная Онкология. 2016; 18 (1): 61–66.
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Аннотация
Таргетная терапия иматинибом является стандартом лечения больных метастатическими гастроинтестинальными стромальными опухолями (ГИСО). Роль хирургического метода в лечении больных диссеминированными ГИСО на сегодняшний день остается одним из актуальных и спорных вопросов. Для оценки эффективности хирургического лечения проведен ретроспективный анализ результатов лечения 140 больных диссеминированными ГИСО. Хирургическое лечение в комбинации с таргетной терапией проводилось 98 больным, 42 – лечение исключительно тирозинкиназными ингибиторами. При сравнительном анализе отмечено статистически значимое улучшение отдаленных результатов в группе больных, которым проводилось хирургическое лечение на фоне эффекта терапии тирозинкиназными ингибиторами. Циторедуктивные операции у больных с диффузной прогрессией на фоне терапии иматинибом не приводят к улучшению показателей выживаемости.
Ключевые слова: гастроинтестинальные стромальные опухоли, стромальные опухоли желудочно-кишечного тракта, иматиниб, хирургическое лечение.
Key words: gastrointestinal stromal tumors, gastrointestinal stromal tumors of the gastrointestinal tract, imatinib, surgical treatment.
Ключевые слова: гастроинтестинальные стромальные опухоли, стромальные опухоли желудочно-кишечного тракта, иматиниб, хирургическое лечение.
________________________________________________
Key words: gastrointestinal stromal tumors, gastrointestinal stromal tumors of the gastrointestinal tract, imatinib, surgical treatment.
Полный текст
Список литературы
1. Demetri GD. Identification and treatment of chemoresistant inoperable or metastatic GIST: experience with the selective tyrosine kinase inhibitor imatinib mesylate (STI571). Eur J Cancer 2002; 38 (Suppl. 5): 52–S59.
2. Duensing A, Medeiros F, Mc Conarty B. Mechanisms of oncogenic KIT signal transduction in primary gastrointestinal stromal tumours (GISTs). Oncogene 2004; 23: 3999–4006.
3. Debiec-Rychter M, Dumez H, Judson I. Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2004; 40: 689–95.
4. Demetri GD, von Mehren M, Blanke CDN. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. Engl J Med 2002; 347: 472–80.
5. Huizinga JD. Gastrointestinal peristalsis: joint action of enteric nerves, smooth muscle, and interstitial cells of Cajal. Microsc Res Tech 1999; 47: 239–47.
6. Tarn C, Skorobogatko YV, Taguchi T et al. Therapeutic effect of imatinib in gastrointestinal stromal tumors: AKT signaling dependent and independent mechanisms. Cancer Res 2006; 66: 5477–86.
7. Verweij J,Casali PG, Zalcberg J et al. Progression-free survival in gastrointestinal stromal tumours withhigh-doseimatinib: randomized trial. Lancet 2004; 364: 1127–34.
8. Blanke CD, Rankin C, Demetri GD et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosinekinase: S0033. J Clin Oncol 2008; 26: 626–32.
9. Wardelmann E, Merkelbach-Bruse S, Pauls K et al. Polyclonal evolution of multiple secondary KIT mutations In gastrointestinal stromal tumors under treatment with imatinib mesylate. Clin Cancer Res 2006; 12: 1743–9.
10. Rutkowski P, Nowecki Z, Nyckowski P et al. Surgical treatment of Patients with initially inoperable and/or metastatic gastrointestinal Stromal tumors (GIST) during therapy with imatinib mesylate. J Surg Oncol 2006; 93: 304–11.
11. Raut CP, Posner M, Desai J et al. Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors. J Clin Oncol 2006; 24: 2325–31.
12. Blanke CD, Demetri GD, von Mehren M et al. Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol 2008; 26: 620–5.
13. Bonvalot S, Eldweny H, Pechoux CL et al. Impact of surgery on advanced gastrointestinal stromal tumors (GIST) in the imatinib era. Ann Surg Oncol 2006; 13: 1596–603.
14. Raut CP, Posner M, Desai J et al. Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors. J Clin Oncol 2006; 24: 2325–31.
15. Rutkowski P, Nowecki Z, Nyckowski P et al. Surgical treatment of patients with initially inoperable and/or metastatic gastrointestinal stromal tumors (GIST) during therapy with imatinib mesylate. J Surg Oncol 2006; 93: 304–11.
16. Andtbacka RH, Ng CS, Scaife CL et al. Surgical resection of gastrointestinal stromal tumors after treatment with imatinib. Ann Surg Oncol 2007; 14: 14–24.
17. Gronchi A, Fiore M, Miselli F et al. Surgery of residual disease following molecular-targeted therapy with imatinib mesylate in advanced/ metastatic GIST. Ann Surg 2007; 245: 341–6.
18. DeMatteo RP, Maki RG, Singer S et al. Results of tyrosine kinase inhibitor therapy followed by surgical resection for metastatic gastrointestinal stromal tumor. Ann Surg 2007; 245: 347–52.
19. Mearadji A, den Bakker MA, van Geel AN et al. Decrease of CD117 expression as possible prognostic marker for recurrence in the resected specimen after imatinib treatment in patients with initially unresectable gastrointestinal stromal tumors: a clinicopathological analysis. Anticancer Drugs 2008; 19: 607–12.
20. Mussi C, Ronellenfitsch U, Jakob J et al. Post-imatinib surgery in advanced/ metastatic GIST: is it worthwhile in all patients? Ann Oncol 2010; 21: 403–8.
21. Ng EH, Pollock RE, Munsell MF et al. Prognostic factors influencing survival in gastrointestinal leiomyosarcomas. Implications for surgical management and staging. Ann Surg 1992; 215: 68–77.
22. Yeh CN, Chen TW, Tseng JH et al. Surgical management in metastatic gastrointestinal stromal tumor (GIST) patients after imatinib mesylate treatment. J Surg Oncol 2010; 102: 599–603.
23. Ronald Tielen, Cornelis Verhoef, Frits van Coevorden. Surgery after treatment with imatinib and/or sunitinib in patients with metastasized gastrointestinal stromal tumors: is it worthwhile? World J Surg Oncol 2012; 10: 111. http://www.wjso.com/content/10/1/111
24. DeMatteo RP, Shah A, Fong Y et al. Results of hepatic resection for sarcoma metastatic to liver. Ann Surg 2001; 234: 540–7.
25. Demetri GD, von Mehren M, Blanke CD et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. NEJM 2002; 347: 472–80.
26. Van Oosterom AT, Judson I, Verweij J et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumors; a phase I study. Lancet 2001; 358: 1421–3.
27. Verweij J, Casali PG, Zalcberg J et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: Randomised trial. Lancet 2004; 364: 1127–34.
2. Duensing A, Medeiros F, Mc Conarty B. Mechanisms of oncogenic KIT signal transduction in primary gastrointestinal stromal tumours (GISTs). Oncogene 2004; 23: 3999–4006.
3. Debiec-Rychter M, Dumez H, Judson I. Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2004; 40: 689–95.
4. Demetri GD, von Mehren M, Blanke CDN. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. Engl J Med 2002; 347: 472–80.
5. Huizinga JD. Gastrointestinal peristalsis: joint action of enteric nerves, smooth muscle, and interstitial cells of Cajal. Microsc Res Tech 1999; 47: 239–47.
6. Tarn C, Skorobogatko YV, Taguchi T et al. Therapeutic effect of imatinib in gastrointestinal stromal tumors: AKT signaling dependent and independent mechanisms. Cancer Res 2006; 66: 5477–86.
7. Verweij J,Casali PG, Zalcberg J et al. Progression-free survival in gastrointestinal stromal tumours withhigh-doseimatinib: randomized trial. Lancet 2004; 364: 1127–34.
8. Blanke CD, Rankin C, Demetri GD et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosinekinase: S0033. J Clin Oncol 2008; 26: 626–32.
9. Wardelmann E, Merkelbach-Bruse S, Pauls K et al. Polyclonal evolution of multiple secondary KIT mutations In gastrointestinal stromal tumors under treatment with imatinib mesylate. Clin Cancer Res 2006; 12: 1743–9.
10. Rutkowski P, Nowecki Z, Nyckowski P et al. Surgical treatment of Patients with initially inoperable and/or metastatic gastrointestinal Stromal tumors (GIST) during therapy with imatinib mesylate. J Surg Oncol 2006; 93: 304–11.
11. Raut CP, Posner M, Desai J et al. Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors. J Clin Oncol 2006; 24: 2325–31.
12. Blanke CD, Demetri GD, von Mehren M et al. Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol 2008; 26: 620–5.
13. Bonvalot S, Eldweny H, Pechoux CL et al. Impact of surgery on advanced gastrointestinal stromal tumors (GIST) in the imatinib era. Ann Surg Oncol 2006; 13: 1596–603.
14. Raut CP, Posner M, Desai J et al. Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors. J Clin Oncol 2006; 24: 2325–31.
15. Rutkowski P, Nowecki Z, Nyckowski P et al. Surgical treatment of patients with initially inoperable and/or metastatic gastrointestinal stromal tumors (GIST) during therapy with imatinib mesylate. J Surg Oncol 2006; 93: 304–11.
16. Andtbacka RH, Ng CS, Scaife CL et al. Surgical resection of gastrointestinal stromal tumors after treatment with imatinib. Ann Surg Oncol 2007; 14: 14–24.
17. Gronchi A, Fiore M, Miselli F et al. Surgery of residual disease following molecular-targeted therapy with imatinib mesylate in advanced/ metastatic GIST. Ann Surg 2007; 245: 341–6.
18. DeMatteo RP, Maki RG, Singer S et al. Results of tyrosine kinase inhibitor therapy followed by surgical resection for metastatic gastrointestinal stromal tumor. Ann Surg 2007; 245: 347–52.
19. Mearadji A, den Bakker MA, van Geel AN et al. Decrease of CD117 expression as possible prognostic marker for recurrence in the resected specimen after imatinib treatment in patients with initially unresectable gastrointestinal stromal tumors: a clinicopathological analysis. Anticancer Drugs 2008; 19: 607–12.
20. Mussi C, Ronellenfitsch U, Jakob J et al. Post-imatinib surgery in advanced/ metastatic GIST: is it worthwhile in all patients? Ann Oncol 2010; 21: 403–8.
21. Ng EH, Pollock RE, Munsell MF et al. Prognostic factors influencing survival in gastrointestinal leiomyosarcomas. Implications for surgical management and staging. Ann Surg 1992; 215: 68–77.
22. Yeh CN, Chen TW, Tseng JH et al. Surgical management in metastatic gastrointestinal stromal tumor (GIST) patients after imatinib mesylate treatment. J Surg Oncol 2010; 102: 599–603.
23. Ronald Tielen, Cornelis Verhoef, Frits van Coevorden. Surgery after treatment with imatinib and/or sunitinib in patients with metastasized gastrointestinal stromal tumors: is it worthwhile? World J Surg Oncol 2012; 10: 111. http://www.wjso.com/content/10/1/111
24. DeMatteo RP, Shah A, Fong Y et al. Results of hepatic resection for sarcoma metastatic to liver. Ann Surg 2001; 234: 540–7.
25. Demetri GD, von Mehren M, Blanke CD et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. NEJM 2002; 347: 472–80.
26. Van Oosterom AT, Judson I, Verweij J et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumors; a phase I study. Lancet 2001; 358: 1421–3.
27. Verweij J, Casali PG, Zalcberg J et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: Randomised trial. Lancet 2004; 364: 1127–34.
2. Duensing A, Medeiros F, Mc Conarty B. Mechanisms of oncogenic KIT signal transduction in primary gastrointestinal stromal tumours (GISTs). Oncogene 2004; 23: 3999–4006.
3. Debiec-Rychter M, Dumez H, Judson I. Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2004; 40: 689–95.
4. Demetri GD, von Mehren M, Blanke CDN. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. Engl J Med 2002; 347: 472–80.
5. Huizinga JD. Gastrointestinal peristalsis: joint action of enteric nerves, smooth muscle, and interstitial cells of Cajal. Microsc Res Tech 1999; 47: 239–47.
6. Tarn C, Skorobogatko YV, Taguchi T et al. Therapeutic effect of imatinib in gastrointestinal stromal tumors: AKT signaling dependent and independent mechanisms. Cancer Res 2006; 66: 5477–86.
7. Verweij J,Casali PG, Zalcberg J et al. Progression-free survival in gastrointestinal stromal tumours withhigh-doseimatinib: randomized trial. Lancet 2004; 364: 1127–34.
8. Blanke CD, Rankin C, Demetri GD et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosinekinase: S0033. J Clin Oncol 2008; 26: 626–32.
9. Wardelmann E, Merkelbach-Bruse S, Pauls K et al. Polyclonal evolution of multiple secondary KIT mutations In gastrointestinal stromal tumors under treatment with imatinib mesylate. Clin Cancer Res 2006; 12: 1743–9.
10. Rutkowski P, Nowecki Z, Nyckowski P et al. Surgical treatment of Patients with initially inoperable and/or metastatic gastrointestinal Stromal tumors (GIST) during therapy with imatinib mesylate. J Surg Oncol 2006; 93: 304–11.
11. Raut CP, Posner M, Desai J et al. Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors. J Clin Oncol 2006; 24: 2325–31.
12. Blanke CD, Demetri GD, von Mehren M et al. Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol 2008; 26: 620–5.
13. Bonvalot S, Eldweny H, Pechoux CL et al. Impact of surgery on advanced gastrointestinal stromal tumors (GIST) in the imatinib era. Ann Surg Oncol 2006; 13: 1596–603.
14. Raut CP, Posner M, Desai J et al. Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors. J Clin Oncol 2006; 24: 2325–31.
15. Rutkowski P, Nowecki Z, Nyckowski P et al. Surgical treatment of patients with initially inoperable and/or metastatic gastrointestinal stromal tumors (GIST) during therapy with imatinib mesylate. J Surg Oncol 2006; 93: 304–11.
16. Andtbacka RH, Ng CS, Scaife CL et al. Surgical resection of gastrointestinal stromal tumors after treatment with imatinib. Ann Surg Oncol 2007; 14: 14–24.
17. Gronchi A, Fiore M, Miselli F et al. Surgery of residual disease following molecular-targeted therapy with imatinib mesylate in advanced/ metastatic GIST. Ann Surg 2007; 245: 341–6.
18. DeMatteo RP, Maki RG, Singer S et al. Results of tyrosine kinase inhibitor therapy followed by surgical resection for metastatic gastrointestinal stromal tumor. Ann Surg 2007; 245: 347–52.
19. Mearadji A, den Bakker MA, van Geel AN et al. Decrease of CD117 expression as possible prognostic marker for recurrence in the resected specimen after imatinib treatment in patients with initially unresectable gastrointestinal stromal tumors: a clinicopathological analysis. Anticancer Drugs 2008; 19: 607–12.
20. Mussi C, Ronellenfitsch U, Jakob J et al. Post-imatinib surgery in advanced/ metastatic GIST: is it worthwhile in all patients? Ann Oncol 2010; 21: 403–8.
21. Ng EH, Pollock RE, Munsell MF et al. Prognostic factors influencing survival in gastrointestinal leiomyosarcomas. Implications for surgical management and staging. Ann Surg 1992; 215: 68–77.
22. Yeh CN, Chen TW, Tseng JH et al. Surgical management in metastatic gastrointestinal stromal tumor (GIST) patients after imatinib mesylate treatment. J Surg Oncol 2010; 102: 599–603.
23. Ronald Tielen, Cornelis Verhoef, Frits van Coevorden. Surgery after treatment with imatinib and/or sunitinib in patients with metastasized gastrointestinal stromal tumors: is it worthwhile? World J Surg Oncol 2012; 10: 111. http://www.wjso.com/content/10/1/111
24. DeMatteo RP, Shah A, Fong Y et al. Results of hepatic resection for sarcoma metastatic to liver. Ann Surg 2001; 234: 540–7.
25. Demetri GD, von Mehren M, Blanke CD et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. NEJM 2002; 347: 472–80.
26. Van Oosterom AT, Judson I, Verweij J et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumors; a phase I study. Lancet 2001; 358: 1421–3.
27. Verweij J, Casali PG, Zalcberg J et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: Randomised trial. Lancet 2004; 364: 1127–34.
________________________________________________
2. Duensing A, Medeiros F, Mc Conarty B. Mechanisms of oncogenic KIT signal transduction in primary gastrointestinal stromal tumours (GISTs). Oncogene 2004; 23: 3999–4006.
3. Debiec-Rychter M, Dumez H, Judson I. Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2004; 40: 689–95.
4. Demetri GD, von Mehren M, Blanke CDN. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. Engl J Med 2002; 347: 472–80.
5. Huizinga JD. Gastrointestinal peristalsis: joint action of enteric nerves, smooth muscle, and interstitial cells of Cajal. Microsc Res Tech 1999; 47: 239–47.
6. Tarn C, Skorobogatko YV, Taguchi T et al. Therapeutic effect of imatinib in gastrointestinal stromal tumors: AKT signaling dependent and independent mechanisms. Cancer Res 2006; 66: 5477–86.
7. Verweij J,Casali PG, Zalcberg J et al. Progression-free survival in gastrointestinal stromal tumours withhigh-doseimatinib: randomized trial. Lancet 2004; 364: 1127–34.
8. Blanke CD, Rankin C, Demetri GD et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosinekinase: S0033. J Clin Oncol 2008; 26: 626–32.
9. Wardelmann E, Merkelbach-Bruse S, Pauls K et al. Polyclonal evolution of multiple secondary KIT mutations In gastrointestinal stromal tumors under treatment with imatinib mesylate. Clin Cancer Res 2006; 12: 1743–9.
10. Rutkowski P, Nowecki Z, Nyckowski P et al. Surgical treatment of Patients with initially inoperable and/or metastatic gastrointestinal Stromal tumors (GIST) during therapy with imatinib mesylate. J Surg Oncol 2006; 93: 304–11.
11. Raut CP, Posner M, Desai J et al. Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors. J Clin Oncol 2006; 24: 2325–31.
12. Blanke CD, Demetri GD, von Mehren M et al. Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol 2008; 26: 620–5.
13. Bonvalot S, Eldweny H, Pechoux CL et al. Impact of surgery on advanced gastrointestinal stromal tumors (GIST) in the imatinib era. Ann Surg Oncol 2006; 13: 1596–603.
14. Raut CP, Posner M, Desai J et al. Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors. J Clin Oncol 2006; 24: 2325–31.
15. Rutkowski P, Nowecki Z, Nyckowski P et al. Surgical treatment of patients with initially inoperable and/or metastatic gastrointestinal stromal tumors (GIST) during therapy with imatinib mesylate. J Surg Oncol 2006; 93: 304–11.
16. Andtbacka RH, Ng CS, Scaife CL et al. Surgical resection of gastrointestinal stromal tumors after treatment with imatinib. Ann Surg Oncol 2007; 14: 14–24.
17. Gronchi A, Fiore M, Miselli F et al. Surgery of residual disease following molecular-targeted therapy with imatinib mesylate in advanced/ metastatic GIST. Ann Surg 2007; 245: 341–6.
18. DeMatteo RP, Maki RG, Singer S et al. Results of tyrosine kinase inhibitor therapy followed by surgical resection for metastatic gastrointestinal stromal tumor. Ann Surg 2007; 245: 347–52.
19. Mearadji A, den Bakker MA, van Geel AN et al. Decrease of CD117 expression as possible prognostic marker for recurrence in the resected specimen after imatinib treatment in patients with initially unresectable gastrointestinal stromal tumors: a clinicopathological analysis. Anticancer Drugs 2008; 19: 607–12.
20. Mussi C, Ronellenfitsch U, Jakob J et al. Post-imatinib surgery in advanced/ metastatic GIST: is it worthwhile in all patients? Ann Oncol 2010; 21: 403–8.
21. Ng EH, Pollock RE, Munsell MF et al. Prognostic factors influencing survival in gastrointestinal leiomyosarcomas. Implications for surgical management and staging. Ann Surg 1992; 215: 68–77.
22. Yeh CN, Chen TW, Tseng JH et al. Surgical management in metastatic gastrointestinal stromal tumor (GIST) patients after imatinib mesylate treatment. J Surg Oncol 2010; 102: 599–603.
23. Ronald Tielen, Cornelis Verhoef, Frits van Coevorden. Surgery after treatment with imatinib and/or sunitinib in patients with metastasized gastrointestinal stromal tumors: is it worthwhile? World J Surg Oncol 2012; 10: 111. http://www.wjso.com/content/10/1/111
24. DeMatteo RP, Shah A, Fong Y et al. Results of hepatic resection for sarcoma metastatic to liver. Ann Surg 2001; 234: 540–7.
25. Demetri GD, von Mehren M, Blanke CD et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. NEJM 2002; 347: 472–80.
26. Van Oosterom AT, Judson I, Verweij J et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumors; a phase I study. Lancet 2001; 358: 1421–3.
27. Verweij J, Casali PG, Zalcberg J et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: Randomised trial. Lancet 2004; 364: 1127–34.
Авторы
О.Б.Абу-Хайдар*1, С.Н.Неред1,2, П.П.Архири1,2, М.П.Никулин1, И.С.Стилиди1,2
1 ФГБУ Российский онкологический научный центр им. Н.Н.Блохина Минздрава России. 115478, Россия, Москва, Каширское ш., д. 23;
2 ГБОУ ВПО Российская медицинская академия последипломного образования Минздрава России. 125993, Россия, Москва, ул. Баррикадная, д. 2/1
*abouhaidar@yandex.ru
1 N.N.Blokhin Russian Cancer Research Center of the Ministry of Health of the Russian Federation. 115478, Russian Federation, Moscow, Kashirskoe sh., d. 23;
2 Russian Medical Academy of Postgraduate Education of the Ministry of Health of the Russian Federation. 125993, Russian Federation, Moscow, ul. Barrikadnaia, d. 2/1
*abouhaidar@yandex.ru
1 ФГБУ Российский онкологический научный центр им. Н.Н.Блохина Минздрава России. 115478, Россия, Москва, Каширское ш., д. 23;
2 ГБОУ ВПО Российская медицинская академия последипломного образования Минздрава России. 125993, Россия, Москва, ул. Баррикадная, д. 2/1
*abouhaidar@yandex.ru
________________________________________________
1 N.N.Blokhin Russian Cancer Research Center of the Ministry of Health of the Russian Federation. 115478, Russian Federation, Moscow, Kashirskoe sh., d. 23;
2 Russian Medical Academy of Postgraduate Education of the Ministry of Health of the Russian Federation. 125993, Russian Federation, Moscow, ul. Barrikadnaia, d. 2/1
*abouhaidar@yandex.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.